Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

REGEND001 Autologous Basal Layer Stem Cell Transplantation for Interstitial Lung Disease (ILD): A Translational Application Study

NCT06998706 is registered in ClinicalTrials.gov with Ruijin Hospital as lead sponsor.

NCT NCT06998706
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06998706 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
REGEND001 Autologous Basal Layer Stem Cell Transplantation for Interstitial Lung Disease (ILD): A Translational Application Study
Lead sponsor
Ruijin Hospital
Phase
Phase 1
Overall status
Recruiting
Start date
June 19, 2025
Completion date
June 30, 2029
Enrollment
10 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

interstitial lung disease (ild)